Gene:
RARA
retinoic acid receptor, alpha

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.


Annotated Labels

  1. FDA Label for arsenic trioxide and PML,RARA
  2. FDA Label for tretinoin and PML,RARA
  3. EMA Label for arsenic trioxide and PML,RARA
  4. PMDA Label for arsenic trioxide and PML,RARA
  5. PMDA Label for tretinoin and PML,RARA
  6. HCSC Label for arsenic trioxide and PML,RARA
  7. HCSC Label for tretinoin and PML,RARA

last updated 10/25/2013

1. FDA Label for arsenic trioxide and PML,RARA

Genetic testing required

Summary

The FDA-approved drug label for arsenic trioxide (Trisenox) contains information regarding indication of the drug in patients whose acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. The label also states that some patients treated with arsenic trioxide have experienced symptoms similar to a syndrome called the retinoic-acid-Acute Promyelocytic Leukemia (RA-APL) or APL differentiation syndrome, which can be fatal, and high-dose steroids (dexamethasone 10 mg intravenously BID) should be immediately initiated at the first signs.

There's more of this label. Read more.


last updated 10/25/2013

2. FDA Label for tretinoin and PML,RARA

Genetic testing required

Summary

Tretinoin is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.

There's more of this label. Read more.


last updated 10/25/2013

3. EMA Label for arsenic trioxide and PML,RARA

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) contains pharmacogenetic information regarding the indication of arsenic trioxide in patients with APL characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RAR-alpha gene.

There's more of this label. Read more.


4. PMDA Label for arsenic trioxide and PML,RARA

Genetic testing required

Summary

Arsenic trioxide is indicated for treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). The PMDA package insert for arsenic trioxide states that patients with APL should be characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

There's more of this label. Read more.


5. PMDA Label for tretinoin and PML,RARA

Informative PGx

Summary

Tretinoin is indicated for the treatment of acute promyelocytic leukemia (APL). The PMDA package insert for tretinoin notes that it acts on the PML-RARa fusion gene, allowing immature promyelocytes to differentiate into normal mature blood cells.

There's more of this label. Read more.


6. HCSC Label for arsenic trioxide and PML,RARA

Genetic testing required

Summary

The product monograph for arsenic trioxide (TRISENOX) states that is indicated for patients with acute promyelotic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic-acid-receptor alpha (PML-RARa) gene expression.

There's more of this label. Read more.


7. HCSC Label for tretinoin and PML,RARA

Genetic testing required

Summary

Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  None
Alternate Symbols:  NR1B1; RAR
PharmGKB Accession Id: PA34225

Details

Cytogenetic Location: chr17 : q21.2 - q21.2
GP mRNA Boundary: chr17 : 38465423 - 38513895
GP Gene Boundary: chr17 : 38455423 - 38516895
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasms

Publications related to RARA: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009. Wang Siqing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The cancer biomarker problem. Nature. 2008. Sawyers Charles L. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood. 1998. Imaizumi M, et al. PubMed

LinkOuts

NCBI Gene:
5914
OMIM:
180240
612376
UCSC Genome Browser:
NM_000964
RefSeq RNA:
NM_000964
NM_001024809
NM_001145301
NM_001145302
RefSeq Protein:
NP_000955
NP_001019980
NP_001138773
NP_001138774
RefSeq DNA:
NT_010783
HuGE:
RARA
Comparative Toxicogenomics Database:
5914
ModBase:
P10276
HumanCyc Gene:
HS05562
HGNC:
9864

Common Searches